ERBB3 and lung carcinoma: It was shown by Littlefield et al. that this mutation increases the activator function of EGFR and given the role EGFR plays in the progression of lung cancer, it is possible that mutant HER3 could be a resistance mechanism to EGFR targeted therapies [116,117].